Illia Nasinnyk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Illia Nasinnyk has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Andrii R. Korol
Division of Research of Laser Biologic Action and Application in Ophthalmology, State Institution "THE Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine", Odesa, Ukraine
4 shared publications - Oleg Zadorozhnyy
Department of Biological Effects and Laser Applications, The Filatov Institute of Eye Diseases and Tissue Therapy of NAMS of Ukraine, Odesa
4 shared publications - Nataliya Pasyechnikova
Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine
2 shared publications SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"
2 shared publications- Taras Kustryn
Laser Microsurgery Department, The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine, Odesa, Ukraine
2 shared publications - A. O. Nevska
SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine
1 shared publication
Latest Publications
- Open Access
- 23 June 2025
- Published by Ukrainian Society of Ophthalmologists in Oftalmologicheskii Zhurnal
- No. 3,p. 3-10
Efficacy of modified diode transscleral cyclophotocoagulation in patients with painful neovascular glaucoma secondary to retinal vein occlusion
Purpose: To assess the efficacy (success rate) of modified diode transscleral cyclophotocoagulation (TSCPC) in patients with painful neovascular glaucoma (NVG) secondary to retinal vein occlusion (RVO). Material and Methods: This prospective, single-center cohort study included 62 patients (62 eyes) with NVG secondary to RVO. Best-corrected visual acuity (BCVA), the number of intraocular pressure (IOP)-lowering medications, laboratory characteristics and pain scores were assessed. A diode laser TSCPC with a fiber optic G-probe was performed at a power of 1,000 mW for duration of 1.5 s (corresponding to 1.5 J/pulse). Post-TSCPC measures of success included IOP between 10 and 21 mmHg or a reduction in IOP of ≥ 30% from baseline IOP, no ocular pain and improvement in or maintenance of BCVA. Results: At 12 months after TSCPC, the IOP decreased by 48% (р = 0.000). Eight (13%), 18 (29%), and 7 (11%) eyes received two, three, and four CPC sessions, respectively. Post-TSCPC complications included long-term inflammation was noted in 6 eyes (9.7%) and hyphema in 1 eye (1.6%). Multivariate regression analysis demonstrated that TSCPC success depended on the baseline IOP (р = 0.01), number of local IOP-lowering medications (р = 0.03), and presence of preoperative complications (р = 0.02), and was associated with a D-dimer value < 0.55 mg fibrinogen equivalent units/l (р = 0.01). Panretinal laser photocoagulation performed early (within 3 months) after RVO and combined with antiangiogenic therapy did not prevent NVG, but contributed to the success of TSCPC for NVG. Conclusion: The success rate of modified diode TSCPC in patients with painful NVG secondary to RVO at 12 months was 71%. Modified diode TSCPC in painful NVG secondary to RVO appears to be safe in terms of the absence of serious complications (hypotony and phthisis bulbi). TSCPC success depends on the presence of ophthalmic and systemic complications which should be treated.
- 23 June 2025
- Published by Ukrainian Society of Ophthalmologists in Oftalmologicheskii Zhurnal
- No. 3,p. 3-10
Open AccessEfficacy of modified diode transscleral cyclophotocoagulation in patients with painful neovascular glaucoma secondary to retinal vein occlusion
Purpose: To assess the efficacy (success rate) of modified diode transscleral cyclophotocoagulation (TSCPC) in patients with painful neovascular glaucoma (NVG) secondary to retinal vein occlusion (RVO). Material and Methods: This prospective, single-center cohort study included 62 patients (62 eyes) with NVG secondary to RVO. Best-corrected visual acuity (BCVA), the number of intraocular pressure (IOP)-lowering medications, laboratory characteristics and pain scores were assessed. A diode laser TSCPC with a fiber optic G-probe was performed at a power of 1,000 mW for duration of 1.5 s (corresponding to 1.5 J/pulse). Post-TSCPC measures of success included IOP between 10 and 21 mmHg or a reduction in IOP of ≥ 30% from baseline IOP, no ocular pain and improvement in or maintenance of BCVA. Results: At 12 months after TSCPC, the IOP decreased by 48% (р = 0.000). Eight (13%), 18 (29%), and 7 (11%) eyes received two, three, and four CPC sessions, respectively. Post-TSCPC complications included long-term inflammation was noted in 6 eyes (9.7%) and hyphema in 1 eye (1.6%). Multivariate regression analysis demonstrated that TSCPC success depended on the baseline IOP (р = 0.01), number of local IOP-lowering medications (р = 0.03), and presence of preoperative complications (р = 0.02), and was associated with a D-dimer value < 0.55 mg fibrinogen equivalent units/l (р = 0.01). Panretinal laser photocoagulation performed early (within 3 months) after RVO and combined with antiangiogenic therapy did not prevent NVG, but contributed to the success of TSCPC for NVG. Conclusion: The success rate of modified diode TSCPC in patients with painful NVG secondary to RVO at 12 months was 71%. Modified diode TSCPC in painful NVG secondary to RVO appears to be safe in terms of the absence of serious complications (hypotony and phthisis bulbi). TSCPC success depends on the presence of ophthalmic and systemic complications which should be treated.
- Open Access
- 20 August 2024
- Published by Ukrainian Society of Ophthalmologists in Oftalmologicheskii Zhurnal
- Vol. 111 (4) , 46-51
Clinical outcomes of a treat-and-extend regimen with intravitreal aflibercept injections in patients with choroidal neovascularization secondary to chronic central serous chorioretinopathy
Purpose: To evaluate 12-month clinical outcomes of a treat-and-extend regimen with intravitreal aflibercept injections in patients with occult (type 1) choroidal neovascularization (CNV) secondary to chronic central serous chorioretinopathy (CSC).Methods: This was a prospective observational single-center study involving 24 patients (24 eyes) with occult (type 1) CNV secondary to chronic CSC. All patients received three initial loading doses of intravitreal 2 mg (0.05 ml) aflibercept at 4-weekly intervals, followed by a treat-and-extend protocol. The primary outcome was best-corrected visual acuity (BCVA) at 12 months. Statistical analyses were conducted and graphs were created using Statistica 10.0 software.Results: Mean BCVA increased significantly from 0.44 ± 0.35 at baseline to 0.58 ± 0.3 at month 12 (р = 0.01). At month 12, complete resolution of SRF was observed in 18 eyes (75%). The mean number of intravitreal aflibercept injections over 12 months was 7.5 ± 1.4.Conclusion: Treat-and-extend intravitreal aflibercept is an effective and safe approach for managing patients with occult (type 1) CNV secondary to chronic CSC. Мета. Оцінити клінічні результати інтравітреального введення афліберцепту в режимі «лікуй та подовжуй» у пацієнтів з прихованою (тип 1) субретинальною неоваскулярною мембраною (СНМ) при хронічній центральній серозній хоріоретинопатії (ЦСХРП) на 12-ому місяці спостереження. Матеріал та методи. Дослідження є проспективним, одноцентровим спостереженням 24 пацієнтів (24 ока) з прихованою (тип 1) СНМ на фоні хронічної ЦСХРП. Всім пацієнтам проводились інтравітреальне введення 2 мг (0,05 мл) афліберцепту. Графік лікування був «лікуй та подовжуй» після трьох обов'язкових завантажувальних ін'єкцій з інтервалом в 4 тижні. Головним досліджуваним показником була гострота зору з максимальною корекцією на 12-ому місяці спостереження. Результати. На 12-ому місяці спостереження відмічалось статистично значиме підвищення середньої гостроти зору з 0,44±0,35 до 0,58±0,3 (р=0,01). В кінці спостереження повна резорбція субретинальної рідини була відмічена в 75% (18 очей). Середня кількість інтравітреальних введень афліберцепту за 12 місяців спостереження становила 7,5±1,4.Висновок. Інтравітреальне введення афліберцепту в режимі «лікуй та подовжуй» є ефективним та безпечним методом лікування пацієнтів з прихованою (тип 1) СНМ при хронічній ЦСХРП.
- 20 August 2024
- Published by Ukrainian Society of Ophthalmologists in Oftalmologicheskii Zhurnal
- Vol. 111 (4) , 46-51
Open AccessClinical outcomes of a treat-and-extend regimen with intravitreal aflibercept injections in patients with choroidal neovascularization secondary to chronic central serous chorioretinopathy
Purpose: To evaluate 12-month clinical outcomes of a treat-and-extend regimen with intravitreal aflibercept injections in patients with occult (type 1) choroidal neovascularization (CNV) secondary to chronic central serous chorioretinopathy (CSC).Methods: This was a prospective observational single-center study involving 24 patients (24 eyes) with occult (type 1) CNV secondary to chronic CSC. All patients received three initial loading doses of intravitreal 2 mg (0.05 ml) aflibercept at 4-weekly intervals, followed by a treat-and-extend protocol. The primary outcome was best-corrected visual acuity (BCVA) at 12 months. Statistical analyses were conducted and graphs were created using Statistica 10.0 software.Results: Mean BCVA increased significantly from 0.44 ± 0.35 at baseline to 0.58 ± 0.3 at month 12 (р = 0.01). At month 12, complete resolution of SRF was observed in 18 eyes (75%). The mean number of intravitreal aflibercept injections over 12 months was 7.5 ± 1.4.Conclusion: Treat-and-extend intravitreal aflibercept is an effective and safe approach for managing patients with occult (type 1) CNV secondary to chronic CSC. Мета. Оцінити клінічні результати інтравітреального введення афліберцепту в режимі «лікуй та подовжуй» у пацієнтів з прихованою (тип 1) субретинальною неоваскулярною мембраною (СНМ) при хронічній центральній серозній хоріоретинопатії (ЦСХРП) на 12-ому місяці спостереження. Матеріал та методи. Дослідження є проспективним, одноцентровим спостереженням 24 пацієнтів (24 ока) з прихованою (тип 1) СНМ на фоні хронічної ЦСХРП. Всім пацієнтам проводились інтравітреальне введення 2 мг (0,05 мл) афліберцепту. Графік лікування був «лікуй та подовжуй» після трьох обов'язкових завантажувальних ін'єкцій з інтервалом в 4 тижні. Головним досліджуваним показником була гострота зору з максимальною корекцією на 12-ому місяці спостереження. Результати. На 12-ому місяці спостереження відмічалось статистично значиме підвищення середньої гостроти зору з 0,44±0,35 до 0,58±0,3 (р=0,01). В кінці спостереження повна резорбція субретинальної рідини була відмічена в 75% (18 очей). Середня кількість інтравітреальних введень афліберцепту за 12 місяців спостереження становила 7,5±1,4.Висновок. Інтравітреальне введення афліберцепту в режимі «лікуй та подовжуй» є ефективним та безпечним методом лікування пацієнтів з прихованою (тип 1) СНМ при хронічній ЦСХРП.
- Open Access
- 26 March 2024
- Published by Elsevier in Advances in Ophthalmology Practice and Research
- Vol. 4 (3) , 107-111
Ocular surface heat flux density as a biomarker related to diabetic retinopathy (pilot study)
- 26 March 2024
- Published by Elsevier in Advances in Ophthalmology Practice and Research
- Vol. 4 (3) , 107-111
Open AccessOcular surface heat flux density as a biomarker related to diabetic retinopathy (pilot study)
- Open Access
- 1 January 2024
- Published by Wiley in Journal of Ophthalmology
- Vol. 2024 (1)
Subthreshold Micropulse Laser (577 nm) Therapy with an Individual Approach for Power Titration in Patients with Chronic Central Serous Chorioretinopathy (Pilot Study)
Purpose. To study the safety and effectiveness of subthreshold micropulse (SML) 577 nm laser therapy with an individual power titration in treating patients with chronic central serous chorioretinopathy (CSC). Methods. The study was a prospective, single‐centre observation of 30 patients (30 eyes) with chronic CSC. All patients with chronic CSC were treated with a 577 nm micropulse laser. Individual power parameters for each patient were titrated in a micropulse mode. The primary outcome measure was best‐corrected visual acuity (BCVA) at 6‐month follow‐up. The secondary outcome measures were as follows: central retinal thickness (CRT) and maximum subretinal fluid height (SRFH) according to optical coherence tomography, number of laser sessions, and treatment safety at 6‐month follow‐up. Results. Before treatment, the mean BCVA was 0.35 ± 0.16, the mean CRT was 285 ± 76 µm, and the mean SRFH was 311 ± 85 µm. Six months after 577 nm SML therapy, there was a statistically significant increase in the mean BCVA with the maximum correction to 0.45 ± 0.15 (p = 0.001). The mean CRT and SRFH decreased significantly to 236 ± 45 μm (p = 0.003) and 45 ± 25 μm (p = 0.001), respectively. At the end of the follow‐up, complete resorption of the subretinal fluid was noted in 50% (15 eyes), and in 43% (13 eyes), a decrease in the SRFH was observed. During the entire observation period, 25 patients underwent 1 session of 577 nm SML therapy, 2 patients underwent 2 sessions, and 3 patients underwent the intervention three times. Conclusion. SML 577 nm therapy with individual selection of laser power in a micropulse mode is a safe and effective method of treating patients with chronic CSC. Further studies are needed to test the long‐term safety and efficacy of 577 nm SML therapy with individual power settings in chronic CSC.
- 1 January 2024
- Published by Wiley in Journal of Ophthalmology
- Vol. 2024 (1)
Open AccessSubthreshold Micropulse Laser (577 nm) Therapy with an Individual Approach for Power Titration in Patients with Chronic Central Serous Chorioretinopathy (Pilot Study)
Purpose. To study the safety and effectiveness of subthreshold micropulse (SML) 577 nm laser therapy with an individual power titration in treating patients with chronic central serous chorioretinopathy (CSC). Methods. The study was a prospective, single‐centre observation of 30 patients (30 eyes) with chronic CSC. All patients with chronic CSC were treated with a 577 nm micropulse laser. Individual power parameters for each patient were titrated in a micropulse mode. The primary outcome measure was best‐corrected visual acuity (BCVA) at 6‐month follow‐up. The secondary outcome measures were as follows: central retinal thickness (CRT) and maximum subretinal fluid height (SRFH) according to optical coherence tomography, number of laser sessions, and treatment safety at 6‐month follow‐up. Results. Before treatment, the mean BCVA was 0.35 ± 0.16, the mean CRT was 285 ± 76 µm, and the mean SRFH was 311 ± 85 µm. Six months after 577 nm SML therapy, there was a statistically significant increase in the mean BCVA with the maximum correction to 0.45 ± 0.15 (p = 0.001). The mean CRT and SRFH decreased significantly to 236 ± 45 μm (p = 0.003) and 45 ± 25 μm (p = 0.001), respectively. At the end of the follow‐up, complete resorption of the subretinal fluid was noted in 50% (15 eyes), and in 43% (13 eyes), a decrease in the SRFH was observed. During the entire observation period, 25 patients underwent 1 session of 577 nm SML therapy, 2 patients underwent 2 sessions, and 3 patients underwent the intervention three times. Conclusion. SML 577 nm therapy with individual selection of laser power in a micropulse mode is a safe and effective method of treating patients with chronic CSC. Further studies are needed to test the long‐term safety and efficacy of 577 nm SML therapy with individual power settings in chronic CSC.